New β-lactam antibiotics and β-lactamase inhibitors

Bibliography

• Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother 2010;54:969-76
   PubMed Web of Science ®Google Scholar
• Page MGP. Emerging cephalosporins. Expert Opin Emerg Drugs 2007;12:511-24
   PubMed Web of Science ®Google Scholar
• Meiji Seika Kaisha. Penicillin-binding protein 2x (PBP2x) trypsin digest crystals and proteins suitable for x-ray crystal structure analysis. JP2007169170; 2007
   Google Scholar
• Meiji Seika Kaisha. Crystal of penicillin-binding protein (PBP) 2b from Streptococcus pneumoniae. WO2007114214; 2007
   Google Scholar
• Meiji Seika Kaisha. Sequence of Haemophilus and Escherichia penicillin-binding-protein PBP3 transpeptidase domain. JP2008220317; 2008
   Google Scholar
• Meiji Seika Kaisha. Preparation of a crystal of the transpeptidase domain of the penicillin-binding-protein 3 of Haemophilus influenzae. JP2009292776; 2009
   Google Scholar
• Slocombe B, Basker MJ, Bentley PH, BRL 17421, a novel beta-lactam antibiotic, highly resistant to beta-lactamases, giving high and prolonged serum levels in humans. Antimicrob Agents Chemother 1981;20:38-46
   PubMed Web of Science ®Google Scholar
• Maderazo EG, Judson S, Pasternak H. Late infections of total joint prostheses. A review and recommendations for prevention. Clin Orthopaed Rel Res 1988;229:131-42
   PubMed Web of Science ®Google Scholar
• Hiramatsu K, Asada K, Tateda-Suzuki E, TOC-39 and TOC-50, a novel class of cephalosporin having a hgh binding affinity to the MRSA-specific penicillin-binding protein, PBP2′. 33rd Interscience Conference Antimicrobial Agents and Chemotherapy; New Orleans, LA; 1993. Abstract 888
   Google Scholar
• Hanaki H, Akagi H, Masaru Y, TOC-39, a novel parenteral broad-spectrum cephalosporin with excellent activity against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1995;39:1120-6
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb Co., USA. Preparation of cephalosporin derivatives for use as antibacterial agents. WO9823621; 1998
   Google Scholar
• Fung-Tomc J, Pucci M, Gradelski E, Anti-staphylococcal activity of a novel MRSA (methicillin-resistant Staphylococcus aureus) cephem BMS-247243. 40th Interscience Conference Antimicrobial Agents and Chemotherapy; 2000. Abstract 1063
   Google Scholar
• Hecker SJ, Glinka TW, Cho A, Discovery of RWJ-54428 (MC-02,479), a new cephalosporin active against resistant gram-positive bacteria. J Antibiotics 2000;53:1272-81
   PubMedGoogle Scholar
• Fukuoka T, Koga T, Ishii C, Antibacterial activity of CS-023 against MRSA and Pseudomonas aeruginosa. 42nd Interscience Conference Antimicrobial Agents and Chemotherapy; San Diego, CA; 2002. Abstract F-324
   Google Scholar
• Kawamoto I, Shimoji Y, Kanno O, Synthesis and structure–activity relationships of novel parenteral carbapenems, CS-023 (R-115685) and related compounds containing an amidine moiety. J Antibiotics 2003;56:565-79
   PubMed Web of Science ®Google Scholar
• Page MGP. Anti-MRSA beta-lactams in development. Curr Opin Pharmacol 2006;6:480-5
   PubMed Web of Science ®Google Scholar
• Noel GJ, Bush K, Bagchi P, A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis 2008;46:647-55
   PubMed Web of Science ®Google Scholar
• Noel GJ, Strauss RS, Amsler K, Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother 2008;52:37-44
   PubMed Web of Science ®Google Scholar
• Talbot GH, Thye D, Das A, Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2007;51:3612-16
   PubMed Web of Science ®Google Scholar
• Eckburg P, Friedland HD, Lee J, Focus 1 and 2: randomized, double-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline (CPT) vs ceftriaxone (CRO) in community-acquired pneumonia (CAP). 49th Interscience Conference Antimicrobial Agents and Chemotherapy; San Francisco, CA; 12 – 15 September 2009. Abstract L1345a
   Google Scholar
• Amsler KM, Davies TA, Shang W, In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections. Antimicrob Agents Chemother 2008;52:3418-23
   PubMed Web of Science ®Google Scholar
• Forest Laboratories Holdings Ltd. Compositions and methods of treatment comprising ceftaroline. WO2010025328; 2010
   Google Scholar
• Shandong Kbp Biomedical Co. Preparations of cephalosporin derivatives for treatment of infectious diseases. CN101245077; 2008
   Google Scholar
• Toda A, Ohki H, Yamanaka T, Synthesis and SAR of novel parenteral anti-pseudomonal cephalosporins: discovery of FR264205. Bioorg Med Chem Lett 2008;18:4849-52
   PubMed Web of Science ®Google Scholar
• Livermore DM, Mushtaq S, Ge Y, Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates. Intl J Antimicrob Agents 2009;34:402-6
   PubMed Web of Science ®Google Scholar
• Boucher HW, Talbot GH, Bradley JS, Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48:1-12
   PubMed Web of Science ®Google Scholar
• Landman D, Bratu S, Kochar S, Evolution of antimicrobial resistance among Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae in Brooklyn. NY J Antimicrob Chemother 2007;60:78-82
   PubMedGoogle Scholar
• Astellas Pharma, Inc. Preparation of cephem compounds for therapeutic use in antimicrobial pharmaceutical compositions. WO2007119511; 2007
   Google Scholar
• Shionogi & Co. Preparation of cephalosporins having catechol group as antibacterial agents. WO2010050468; 2010
   Google Scholar
• Harris AM. Catechol-substituted cephalosporins. Curr Opin Invest Drugs 1993;2:109-18
   Google Scholar
• Nikaido H, Rosenberg EY. Cir and Fiu proteins in the outer membrane of Escherichia coli catalyze transport of monomeric catechols: study with beta-lactam antibiotics containing catechol and analogous groups. J Bacteriol 1990;172:1361-7
   PubMed Web of Science ®Google Scholar
• Curtis NA, Eisenstadt RL, East SJ, Iron-regulated outer membrane proteins of Escherichia coli K-12 and mechanism of action of catechol-substituted cephalosporins. Antimicrob Agents Chemother 1988;32:1879-86
   PubMedGoogle Scholar
• Trine Pharmaceuticals, Inc., USA. Preparation of carbacephem beta-lactam antibiotics for the treatment of bacterial infections. WO2004-US13054; 2004
   Google Scholar
• Glinka T, Blais J, Dudley M, A novel series of 3-heteroarylthio carbacephems with activity against resistant Gram-positive bacteria. 45th Interscience Conference Antimicrobial Agents and Chemotherapy; San Francisco, CA; 2005. Abstract 1455
   Google Scholar
• Griffith D, Dudley MN, Glinka T, Preclinical pharmacokinetics and serum protein binding of BP-102 and other members of a novel series of carbacephems active against resistant Gram positive bacteria. 45th Interscience Conference Antimicrobial Agents and Chemotherapy; San Francisco, CA; 2005. Abstract F-1458
   Google Scholar
• Jones RN, Sader HS, Fritsche TR, Antimicrobial activity of BP-102, a novel carbacephem, tested against H. influenzae, M. catarrhalis and various Gram-positive cocci. 45th Interscience Conference Antimicrobial Agents and Chemotherapy; San Francisco, CA; 2005. Abstract F-1457
   Google Scholar
• Blanca Pharmaceuticals. Preparation of carbacephem beta-lactam antibiotics and beta-lactamase inhibitors. US2008146535; 2008
   Google Scholar
• Achaogen. Carbacephem beta-lactam antibiotics. WO2009055696; 2009
   Google Scholar
• Achaogen. Carbacephem beta-lactam antibiotics. WO2010030811; 2010
   Google Scholar
• Achaogen. Carbacephem beta-lactam antibiotics. WO2010030810; 2010
   Google Scholar
• Gootz T, Retsema J, Girard A, In vitro activity of CP-65,207, a new penem antimicrobial agent, in comparison with those of other agents. Antimicrob Agents Chemother 1989;33:1160-6
   PubMedGoogle Scholar
• Retsema J, Girard A, Anderson M, In vitro and in vivo evaluation of a new penem antibiotic: CP-65,207. 38th Interscience Conference Antimicrobial Agents and Chemotherapy; San Diego, CA; 1988. Abstract 221
   Google Scholar
• Pfizer Products, Inc. Preparation of penem prodrugs for the treatment of bacterial infections. WO2008059367; 2008
   Google Scholar
• Wujcik CE, Kadar EP. Reduction of in-source collision-induced dissociation and thermolysis of sulopenem prodrugs for quantitative liquid chromatography/electrospray ionization mass spectrometric analysis by promoting sodium adduct formation. Rapid Commun Mass Spectrom 2008;22:3195-206
   PubMed Web of Science ®Google Scholar
• Clinical Trials.gov; 2009. Available from: http://clinicaltrials.gov/ct2/show?term=sulopenem&rank=1 [Cited 3 August 2010]
   Google Scholar
• Clinical trials.gov; 2010. Available from: http://clinicaltrials.gov/ct2/show/NCT00759564?term=sulopenem&rank=2 [Cited 3 August 2010]
   Google Scholar
• Upchurch J, Rosemore M, Tosiello R, Randomized double-blind study comparing 7- and 10-day regimens of faropenem medoxomil with a 10-day cefuroxime axetil regimen for treatment of acute bacterial sinusitis. Otolaryngol Head Neck Surg 2006;135:511-17
   Google Scholar
• Amplyx Pharmaceuticals. Antimicrobials. WO2010065110; 2010
   Google Scholar
• Germany. Bactericidal anti-MRSA active pharmaceutical composition containing carbapenems. WO2008141764; 2008
   Google Scholar
• Meiji Seika Kaisha. Preparation of 2-ethenylthiocarbapenem derivatives as antibacterial agents. WO2006109823; 2006
   Google Scholar
• Meiji Seika Kaisha. Preparation carbapenems and oral antibacterial agents containing them. JP2008074803; 2008
   Google Scholar
• Kobayashi R, Konomi M, Hasegawa K, In vitro activity of tebipenem, a new oral carbapenem antibiotic, against penicillin-nonsusceptible Streptococcus pneumoniae. Antimicrob Agents Chemother 2005;49:889-94
   PubMed Web of Science ®Google Scholar
• Plantan I, Selic L, Mesar T, 4-Substituted trinems as broad spectrum beta-lactamase inhibitors: structure-based design, synthesis, and biological activity. J Med Chem 2007;50:4113-21
   PubMed Web of Science ®Google Scholar
• Lek Pharmaceuticals D.D. Antibacterial combination of a tricyclic carbapenem and an antibiotic. WO2008098955; 2008
   Google Scholar
• LEK Pharmaceuticals D.D. Preparation of new trinem antibiotics and inhibitors of beta-lactamases. WO2009153297; 2009
   Google Scholar
• Lek Pharmaceuticals D.D. Use of inhibitor of beta-lactamases and its combination with beta-lactam antibiotics for treatment of bacterial infection. WO2009095387; 2009
   Google Scholar
• Lek Pharmaceuticals D.D. Antibacterial combination of a tricyclic carbapenem and an antibiotic. EP1958630; 2008
   Google Scholar
• Paukner S, Hesse L, Prezelj A, In vitro activity of LK-157, a novel tricyclic carbapenem as broad-spectrum beta-lactamase inhibitor. Antimicrob Agents Chemother 2009;53:505-11
   PubMed Web of Science ®Google Scholar
• Lek Pharmaceuticals D.D. Use of inhibitor of beta-lactamases and its combination with beta-lactam antibiotics for treatment of bacterial infection. EP2085084; 2009
   Google Scholar
• Basilea Pharmaceutica A.-G. Useful combinations of monobactam antibiotics with beta-lactamase inhibitors. WO2007065288; 2007
   Google Scholar
• Basilea Pharmaceutica A.-G. Combination medicaments for treating bacterial infections. WO2008116813; 2008
   Google Scholar
• Basilea Pharmaceutica A.-G. Process for the preparation of 2-(primary-/secondary-amino)hydrocarbyl)-carbamoyl-7-oxo-2,6-diazabicyclo[3.2.0.]heptane-6-sulfonic acid derivatives. WO2009071638; 2009
   Google Scholar
• Russo TA, Page MG, Beanan J, BAL30072 is active against Acinetobacter baumannii in a rat soft-tissue infection model. 49th Interscience Conference Antimicrobial Agents and Chemotherapy; San Francisco, CA; 12 – 15 September 2009. Abstract F1-1486
   Google Scholar
• Page MGP, Heim J. New molecules from old classes: revisiting the development of beta-lactams. IDrugs 2009;12:561-5
   Google Scholar
• Page MGP, Dantier C, Desarbre E. In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. Antimicrob Agents Chemother 2010;54:2291-302
   PubMed Web of Science ®Google Scholar
• Bush K, Freudenberger JS, Sykes RB. Interaction of azthreonam and related monobactams with beta-lactamases from gram-negative bacteria. Antimicrob Agents Chemother 1982;22:414-20
   PubMed Web of Science ®Google Scholar
• Glade Organics Private Ltd. Synergistic antibacterial combinations of aztreonam with meropenem or ertapenem. WO2010064261; 2010
   Google Scholar
• Page MGP, Desarbre E, Geier C, Activity of monobactam beta-lactamase inhibitor combinations against beta-lactam-resistant Gram-negative bacteria. 47th Interscience Conference Antimicrobial Agents and Chemotherapy; Chicago, IL; 17 – 20 September 2007. Abstract F1-311
   Google Scholar
• Page MGP, Desarbre E, Geier C, Activity of BAL30376 against Gram-negative bacteria. 47th Interscience Conference Antimicrobial Agents and Chemotherapy; Chicago, IL; 17 – 20 September 2007. Abstract F1-312
   Google Scholar
• Bush K, Macalintal C, Rasmussen BA, Kinetic interactions of tazobactam with beta-lactamases from all major structural classes. Antimicrob Agents Chemother 1993;37:851-8
   PubMed Web of Science ®Google Scholar
• Wyeth. Bicyclic 6-alkylidene-penem beta-lactamase inhibitors and beta-lactam antibiotic combination: a broad spectrum antibiotic. WO2007016134; 2007
   Google Scholar
• Wyeth. Tricyclic 6-alkylidene-penem beta-lactamase inhibitors and beta-lactam antibiotic combination for treatment of resistant infections. US2007027130; 2007
   Google Scholar
• Petersen PJ, Jones CH, Venkatesan AM, Efficacy of piperacillin combined with the penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. Antimicrob Agents Chemother 2009;53:1698-700
   PubMed Web of Science ®Google Scholar
• Petersen PJ, Jones CH, Venkatesan AM, Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. Antimicrob Agents Chemother 2009;53:370-84
   Google Scholar
• Southern Methodist University. Preparation and antibacterial activity of beta-lactamase inhibitory compounds. US2010009954; 2010
   Google Scholar
• Orchid Chemicals & Pharmaceuticals Ltd. Preparation of 2-substituted methyl penam derivatives for the treatment of bacterial infections. US2008015156; 2008
   Google Scholar
• Miossec C, Poirel L, Livermore D, In vitro activity of the new beta-lactamase inhibitor NXL104: restoration of ceftazidime (CAZ) efficacy against carbapenem-resistant Enterobacteriaceae strains. 47th Interscience Conference Antimicrobial Agents and Chemotherapy; Chicago, IL; 17 – 20 September 2007. Abstract F1-318
   Google Scholar
• Livermore DM, Mushtaq S, Warner M, NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum beta-lactamases and carbapenemases. J Antimicrob Chemother 2008;62:1053-56
   PubMed Web of Science ®Google Scholar
• Novexel. Use of (1R,2S,5R)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases. EP2135959; 2009
   Google Scholar
• Levasseur P, Girard AM, Miossec C, Efficacy of NXL104 (previously AVE1330A), a novel broad spectrum beta-lactamase inhibitor, in combination with ceftazidime (CAZ) in murine septicaemia and pneumonia. 45th Interscience Conference Antimicrobial Agents and Chemotherapy; San Francisco, CA; 2005
   Google Scholar
• Novexel. New nitrogen-heterocyclic compounds, their preparation and their use as antibacterial drugs. WO2008142285; 2008
   Google Scholar
• Merck & Co., Inc. 7-Oxo-2,6-Diazabicyclo[3.2.0]heptane-6-sulfonic acid derivatives as beta-lactamase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of bacterial infections. WO2008039420; 2008
   Google Scholar
• Merck & Co., Inc. Preparation of sulfooxydiazabicyclooctanecarboxamide derivatives and analogs for use as beta-lactamase inhibitors. WO2009091856; 2009
   Google Scholar
• Nagarajan R, Pratt RF. Thermodynamic evaluation of a covalently bonded transition state analogue inhibitor: inhibition of beta-lactamases by phosphonates. Biochemistry 2009;43:9664-73
   Google Scholar
• Merck & Co., Inc., USA; Methylgene, Inc. Sulfonylamidomethylphosphonates as inhibitors of beta-lactamases for decreasing of bacterial resistance to antibiotics. WO2007139729; 2007
   Google Scholar
• Merck & Co., Inc., USA; Methlgene, Inc. (Hetero)arylsulfonamidomethylphosphonate derivatives as beta-lactamase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of bacterial infection. WO2008073142; 2008
   Google Scholar
• Protez Pharmaceuticals. Beta-lactamase inhibitors. WO2009064413; 2009
   Google Scholar
• Wouters J, Fonze E, Vermeire M, Crystal structure of Enterobacter cloacae 908R class C beta-lactamase bound to iodo-acetamido-phenyl boronic acid, a transition-state analogue. Cell Molec Life Sci 2003;60:1764-73
   Google Scholar
• Chen Y, Minasov G, Roth TA, The deacylation mechanism of AmpC beta-lactamase at ultrahigh resolution. J Amer Chem Soc 2006;128:2970-6
   PubMed Web of Science ®Google Scholar
• Merck & Co., Inc., USA. Succinic acid derivative metallo-beta-lactamase inhibitors, their preparation, and their use in treating bacterial infections. WO2001030149; 2000
   Google Scholar
• Toney JH, Hammond GG, Fitzgerald PM, Succinic acids as potent inhibitors of plasmid-borne IMP-1 metallo-beta-lactamase. J Biolog Chem 2001;276:31913-18
   PubMed Web of Science ®Google Scholar
• Meiji Seika Kaisha. Preparation of maleic acid derivatives as metallo-beta-lactamase inhibitors. US2008090825; 2008
   Google Scholar
• Morinaka A, Ohkuma K, Matsumoto K, In vivo efficacy of ME1071, a novel metallo-beta-lactamase (MBL) inhibitor, in combination with carbapenems agasint MBL-producing Pseudomonas aeruginosa in a murine pneumonia model. 49th Interscience Conference Antimicrobial Agents and Chemotherapy; San Francisco, CA; 12 – 15 September 2009. Abstract F1-1491
   Google Scholar
• Meiji Seika Kaisha. Pharmaceutical compositions containing maleic acid derivatives and cephem antibiotics. JP2009040743; 2009
   Google Scholar
• Texas Tech University System. Inhibition of metallo-beta-lactamase by double-stranded DNA aptamers and killing beta-lactamase-producing bacteria. WO2007025016; 2007
   Google Scholar
• Kim SK, Sims CL, Wozniak SE, Antibiotic resistance in bacteria: novel metalloenzyme inhibitors. Chem Biol Drug Design 2009;74:343-8
   PubMed Web of Science ®Google Scholar
• Can. Preparation of naphthohydrazides, benzohydrazides and pyridohydrazides as inhibitors of Class B and Class D beta-lactamases. WO2009114921; 2009
   Google Scholar
• Roll DM, Yang Y, Wildey MJ, Inhibition of metallo-beta-lactamases by pyridine monothiocarboxylic acid analogs. J Antibiotics 2010;63:255-7
   Google Scholar
• Orchid Chemicals & Pharmaceuticals Ltd. Process for the preparation of a cephalosporin antibiotic. IN2003MA00502; 2007
   Google Scholar
• Orchid Chemicals & Pharmaceuticals Ltd. An improved process for the preparation of a cephalosporin antibiotic. IN2005CH00052; 2007
   Google Scholar
• Orchid Chemicals & Pharmaceuticals Ltd. Novel electrochemical system for chlorination of azetidinone derivatives. IN2002MA00639; 2007
   Google Scholar
• Orchid Chemicals & Pharmaceuticals Ltd. Improved process for the preparation of the carbapenem antibiotic imipenem. IN2005CH01178; 2007
   Google Scholar
• Orchid Chemicals & Pharmaceuticals Ltd. Process for the preparation of beta-lactam antibiotic Faropenem. WO2008035153; 2008
   Google Scholar
• Ranbaxy Laboratories Ltd. Processes for the preparation of penems and their intermediates. WO2007004028; 2007
   Google Scholar
• Zhejian Jinhua Conba Bio-Pharm Co., Ltd. Method for synthesis of antibacterial agent sodium faropenem. CN1884284; 2006
   Google Scholar
• Jacoby G, Bush K. Beta-lactamase classification and amino acid sequences for TEM, SHV and OXA extended-spectrum and inhibitor resistant enzymes; 2010. Available from: http://www.lahey.org/Studies/ [Cited 4 August 2010]
   Google Scholar
• Pournaras S, Poulou A, Voulgari E, Detection of the new metallo-beta-lactamase VIM-19 along with KPC-2, CMY-2 and CTX-M-15 in Klebsiella pneumoniae. J Antimicrob Chemother 2010;65:1604-7
   Web of Science ®Google Scholar